Contributions
Abstract: P550
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - OCT
Objectives: To explore the relationship between retinal layers" thickness measured through OCT and cognitive function as well as disability in patients with early RRMS.
Methods: Participants in this cross-sectional study were adults with RRMS and disease duration of five years or less, stable on Interferon beta-1a or Fingolimod therapy, and without a history of optic neuritis (ON) in one or both eyes. Patients were evaluated as per standards of care, and additionally underwent a battery of cognitive tests and a retinal OCT scan. A parallel cohort of healthy age and gender matched controls underwent a retinal OCT scan for retinal measurements reference.
Results: We studied 47 patients with RRMS, on Interferon beta-1a (N=32) or Fingolimod (N=15), and 18 healthy controls. Participants were comparable regarding demographic and clinical characteristics. However, the mean (SD) pRNFL and GCIPL thickness in controls [99.5 (8.9) µm, 86.8 (4.2) µm] was greater than that in either Interferon [92.0 (8.7) µm, 79.9 (6.7) µm] or Fingolimod [87.2 (8.4) µm, 75.0 (6.6) µm]-treated patients (p< 0.001). Multivariate analyses controlling for age, gender, disease duration, education, and treatment, showed that pRNFL thickness correlated negatively with EDSS (standardized Beta= -0.35, p= 0.02) and 9HPT (standardized Beta= -0.52, p< 0.001), and positively with SDMT (standardized Beta= 0.42, p= 0.01). GCIPL thickness correlated negatively with 9HPT (standardized Beta= -0.34, p= 0.03).
Conclusion: In patients with early RRMS without optic neuropathy, retinal thickness measures correlated with physical and cognitive disability, supporting their potential as biomarkers of axonal loss and neurodegeneration.
Disclosure: Nabil El Ayoubi: reports no disclosures
Stephanie Ghassan: reports no disclosures
Marianne Said: reports no disclosures
Joelle Allam: reports no disclosures
Hala Darwish: reports no disclosures
Samia J. Khoury: reports no disclosures
Study supported by an unrestricted grant from Novartis pharmaceuticals.
Abstract: P550
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - OCT
Objectives: To explore the relationship between retinal layers" thickness measured through OCT and cognitive function as well as disability in patients with early RRMS.
Methods: Participants in this cross-sectional study were adults with RRMS and disease duration of five years or less, stable on Interferon beta-1a or Fingolimod therapy, and without a history of optic neuritis (ON) in one or both eyes. Patients were evaluated as per standards of care, and additionally underwent a battery of cognitive tests and a retinal OCT scan. A parallel cohort of healthy age and gender matched controls underwent a retinal OCT scan for retinal measurements reference.
Results: We studied 47 patients with RRMS, on Interferon beta-1a (N=32) or Fingolimod (N=15), and 18 healthy controls. Participants were comparable regarding demographic and clinical characteristics. However, the mean (SD) pRNFL and GCIPL thickness in controls [99.5 (8.9) µm, 86.8 (4.2) µm] was greater than that in either Interferon [92.0 (8.7) µm, 79.9 (6.7) µm] or Fingolimod [87.2 (8.4) µm, 75.0 (6.6) µm]-treated patients (p< 0.001). Multivariate analyses controlling for age, gender, disease duration, education, and treatment, showed that pRNFL thickness correlated negatively with EDSS (standardized Beta= -0.35, p= 0.02) and 9HPT (standardized Beta= -0.52, p< 0.001), and positively with SDMT (standardized Beta= 0.42, p= 0.01). GCIPL thickness correlated negatively with 9HPT (standardized Beta= -0.34, p= 0.03).
Conclusion: In patients with early RRMS without optic neuropathy, retinal thickness measures correlated with physical and cognitive disability, supporting their potential as biomarkers of axonal loss and neurodegeneration.
Disclosure: Nabil El Ayoubi: reports no disclosures
Stephanie Ghassan: reports no disclosures
Marianne Said: reports no disclosures
Joelle Allam: reports no disclosures
Hala Darwish: reports no disclosures
Samia J. Khoury: reports no disclosures
Study supported by an unrestricted grant from Novartis pharmaceuticals.